CureVac (CVAC)
(Delayed Data from NSDQ)
$3.23 USD
-0.06 (-1.82%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.25 +0.02 (0.62%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
CVAC 3.23 -0.06(-1.82%)
Will CVAC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CVAC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CVAC
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
CorMedix (CRMD) Reports Q2 Loss, Tops Revenue Estimates
CVAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates
Ontrak, Inc. (OTRK) Reports Q2 Loss, Lags Revenue Estimates
Other News for CVAC
CureVac presents data from dose-escalation Part A of Phase 1 CVGBM vaccine study
GSK, CureVac mRNA flu shot reaches late-stage studies
CureVac-GSK Influenza Vaccine Shows Promise
CureVac, GSK announces Phase 2 data from influenza mRNA vaccine program
Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)